(Reuters) - The Gates Foundation will allocate up to $120 million to help lower-income countries get an experimental COVID-19 drug being developed by U.S. drugmaker Merck & Co Inc in the battle against coronavirus, it said on Wednesday.
The money will support efforts to develop and make generic versions of what could become the first oral antiviral medication for the disease if it wins regulatory approval, the foundation said in a statement.
Already a subscriber? Log in
Get 20% OFF The Star Digital Access
Cancel anytime. Ad-free. Unlimited access with perks.
